ReviewCurrent allergy and asthma reports2021
Hereditary Alpha-Tryptasemia: a Commonly Inherited Modifier of Anaphylaxis.
Review in Current allergy and asthma reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- Article
- Drug-induced anaphylaxis: Molecular pathophysiology, diagnosis, and management.Asia Pacific allergy · 2026Article
- Hereditary Alpha-Tryptasemia and Mastocytosis: What We Know and What We Need To Learn.Current allergy and asthma reports · 2026Review
- Hereditary α-tryptasemia; a review of mechanisms linking α-tryptase gene dosage to intestinal homeostasis and immunopathology.Frontiers in allergy · 2026Review
- Hereditary alpha tryptasemia and clinical implications.World journal of clinical cases · 2025Review
- Describing Clinical Characteristics and Treatment Course of Patients with Hereditary Alpha-tryptasemia: A Single-center Study.Clinical reviews in allergy & immunology · 2025Review
- Defining "Normal" basal serum tryptase levels: a context-dependent approach to improve diagnostics in systemic mastocytosis.Frontiers in allergy · 2025Review
- Hereditary alpha-tryptasemia and monoclonal mast cell disorders.Frontiers in allergy · 2025Review
- Identifying patients at risk of anaphylaxis.The World Allergy Organization journal · 2024Review
- The Clinical Features of Hereditary Alpha-Tryptasemia—Implications for Interdisciplinary Practice.Deutsches Arzteblatt international · 2024Review
- Alpha-Tryptase as a Risk-Modifying Factor for Mast Cell-Mediated Reactions.Current allergy and asthma reports · 2024Review
- Genetic Variants Leading to Urticaria and Angioedema and Associated Biomarkers.The journal of allergy and clinical immunology. In practice · 2023Article
- Mast Cell Activation Syndrome Update-A Dermatological Perspective.Journal of personalized medicine · 2023Review
- Secretory and Membrane-Associated Biomarkers of Mast Cell Activation and Proliferation.International journal of molecular sciences · 2023Review
- Anaphylaxis in elderly people.Current opinion in allergy and clinical immunology · 2022Review
- Histopathology and Molecular Genetics in Systemic Mastocytosis: Implications for Clinical Management.International journal of molecular sciences · 2022Article
- Clinical relevance of inherited genetic differences in human tryptases: Hereditary alpha-tryptasemia and beyond.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2021Review
- Mastocytosis and Mast Cell Activation Disorders: Clearing the Air.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewHereditary alpha-tryptasemia (HαT) is an autosomal dominant genetic trait and a common cause of elevated basal serum tryptase in Western populations. It is a risk factor for severe anaphylaxis among individuals with venom allergy and an established modifier of anaphylaxis and mast cell mediator-associated symptoms among patients with systemic mastocytosis. Understanding the physiology of tryptases and how this may relate to the clinical features associated with HαT is the first step in identifying optimal medical management and targets for novel therapeutics. RECENT
findingsHαT prevalence is increased in both clonal and non-clonal mast cell-associated disorders where it augments symptoms of immediate hypersensitivity, including anaphylaxis. The unique properties of naturally occurring α/β-tryptase heterotetramers may explain certain elements of phenotypes associated with HαT, though additional mechanisms are being evaluated. This review provides an overview of the clinical and translational studies that have identified HαT as a modifier of mast cell-associated disorders and anaphylaxis and discusses mechanisms that may potentially explain some of these clinical findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.